Eli Lilly (LLY) Innovates with GLP-1 Drugs, Driving Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Fool
- Innovation Driving Growth: Eli Lilly's revenue surged to $53.2 billion in the first nine months of 2025, a 9% year-over-year increase, fueled by its GLP-1 products like Mounjaro and Zepbound.
- Broad Future Prospects: The company is developing an oral GLP-1 drug and the promising weight loss treatment retatrutide, which is in late-stage trials and expected to significantly contribute to future earnings.
- Strategic Partnership: Eli Lilly's collaboration with Nvidia to build an AI-driven drug discovery factory highlights its strong appetite for future growth, despite the long timeline for tangible results.
- Diversified Business: In addition to GLP-1 drugs, Eli Lilly's Kisunla for early Alzheimer's treatment enhances its market competitiveness and business stability, showcasing its broad therapeutic portfolio.
Analyst Views on AXP
Wall Street analysts forecast AXP stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AXP is 351.42 USD with a low forecast of 280.00 USD and a high forecast of 400.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
21 Analyst Rating
7 Buy
12 Hold
2 Sell
Hold
Current: 358.260
Low
280.00
Averages
351.42
High
400.00
Current: 358.260
Low
280.00
Averages
351.42
High
400.00
About AXP
American Express Company is a globally integrated payments company with card-issuing, merchant-acquiring and card network businesses. It offers products and services to a range of customers, including consumers, small businesses, mid-sized companies and large corporations around the world. Its segments include U.S. Consumer Services (USCS), Commercial Services (CS), International Card Services (ICS) and Global Merchant and Network Services (GMNS). USCS offers travel and lifestyle services as well as banking and non-card financing products. CS offers payment and expense management, banking and non-card financing products. ICS provides services to international customers, including travel and lifestyle services, and manages certain international joint ventures and its loyalty coalition business. GMNS operates a payments network that processes and settles card transactions, acquires merchants and provides multichannel marketing programs and capabilities, services and data analytics.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
